Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2625 Target Snapshot

Angiotensin-converting enzyme · SINGLE PROTEIN · Rattus norvegicus

599Compounds
220Assays
6Approved Drugs
474.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P47820. Use UniProt P47820 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P47820 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Angiotensin-converting enzyme as ChEMBL target CHEMBL2625, mapped to UniProt P47820. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Angiotensin-converting enzyme
SINGLE PROTEIN · Rattus norvegicus
As of 2026-09-13
ChEMBL target ID
CHEMBL2625
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P47820
Angiotensin-converting enzyme
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Angiotensin-converting enzyme is the right protein anchor across sources, using UniProt P47820 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelAngiotensin-converting enzyme
UniProt AccessionP47820
Component TypeProtein
Sequence Length1313 aa

Angiotensin-converting enzyme

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Angiotensin-converting enzyme, mapped to UniProt P47820. Sequence length is 1313 aa.

Mapped IDP47820
Review nameAngiotensin-converting enzyme
OrganismRattus norvegicus
Clinical Profile

Clinical Phase Distribution

6
Approved
3
Phase II
Assay Mix

Activity Type Distribution

IC50399.0
KI75.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL20341 9.59 IC50 0.26 Preclinical
CHEMBL287896 9.52 IC50 0.3 Preclinical
CHEMBL410980 9.46 IC50 0.35 Preclinical
CHEMBL19951 9.4 IC50 0.4 Preclinical
CHEMBL88278 9.38 IC50 0.42 Preclinical
CHEMBL86884 9.34 IC50 0.46 Preclinical
CHEMBL329125 9.3 IC50 0.5 Preclinical
CHEMBL342372 9.29 IC50 0.51 Clinical
CHEMBL419499 9.26 IC50 0.55 Preclinical
CHEMBL20182 9.24 IC50 0.58 Preclinical
Distribution

pChEMBL Value Distribution

9
5.0
32
5.5
43
6.0
47
6.5
54
7.0
64
7.5
51
8.0
37
8.5
16
9.0
2
9.5
pChEMBL
Approved Drugs

Approved Drugs

SPIRAPRIL
CHEMBL431
Approved 1994
BENAZEPRIL
CHEMBL838
Approved 1991
ENALAPRILAT ANHYDROUS
CHEMBL577
Approved 1988
ENALAPRIL
CHEMBL578
Approved 1985
CAPTOPRIL
CHEMBL1560
Approved 1981
Assay Landscape

Assay Landscape

220
Total Assays
365
Tested Compounds
2
Assay Types
Binding — 180 assays, 365 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 123 6 7.2
single protein format 48 304 7.2
cell-free format 5 14 6.2
assay format 3 16 6.5
tissue-based format 1 25 7.3
Functional — 40 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 34 0
assay format 6 1 8.1

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine